Andrew W. Taylor, PhD
Associate Dean of Research
Boston University School of Medicine

PhD, Ohio State University
MS, Ohio State University




A large part of our research effort has been to characterize the immunosuppressive and immunoregulating factors within the immune privileged eye. Through immunochemical and biological analysis of aqueous humor, the fluid filling the anterior chamber of the eye, and the soluble factors produced by retinal pigment epithelial cells. We have identified several potent immunoregulating and immunosuppressing neuropeptides that:
1. Suppress macrophage-mediated inflammation.
2. Induce activation of myeloid suppressor cells
3. Alter phagocytic pathways within potential Antigen Presenting Cells.
4. Suppress the activation of effector T cells
5. Mediate the induction of antigen-specific regulatory T cells.

Our research has found constitutively present neuropeptides in the immune-privileged eye, alpha-melanocyte stimulating hormone (a-MSH), vasoactive intestinal peptide, calcitonin gene related peptide, and somatostatin. Collectively, the neuropeptides in aqueous humor suppress activation of delayed-type hypersensitivity of adaptive immunity and endotoxin activation of macrophages in innate immunity. Individually, the neuropeptides target different cells at different stages in the induction of immune responses within the immune-privileged eye.

We are finding that the activation of macrophages to pathogens within the ocular microenvironment does not promote inflammation but promotes suppressor functionality in the macrophages. These macrophages respond to pathogens without mediating inflammation or activating T cells. Moreover, the macrophages produce anti-inflammatory cytokines, suppress activation of effector T cells while promoting Treg cell activity.

As we continue to examine the mechanisms of ocular immune privilege, we further promote the importance of the interactions between the nervous and the immune systems and how we can use these interactions therapeutically to manipulate immunity to suppress autoimmune disease.

Professor
Boston University School of Medicine
Ophthalmology


Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences



2019-2024 Association for Research In Vision and Ophthalmology (ARVO): Elected Immunology Member of the Board of Trustees
2019 Association of American Medical Colleges (AAMC): GRAND Steering Committee Member
2015 Association for Research In Vision and Ophthalmology (ARVO): Gold Fellow, an honor to recognize individual members accomplishments, and leadership
2014-2018 NIH: DPVS Study Section Member
2011-2011 Association for Research In Vision and Ophthalmology (ARVO): Elected position for 3 years on the Annual Program Committee for the ARVO annual meeting representin
2010-2015 Association for Research In Vision and Ophthalmology (ARVO): Silver Fellow, an honor established to recognize current ARVO members for their individual accomplis


Manipulation of Immunity to Treat Uveitis
03/01/2020 - 02/29/2024 (PI)
NIH/National Eye Institute
5R01EY025961-06

Initial Mechanism of Action for The Therapeutic Application of Melanocortin Receptor Agonists to Reset Immune Tolerance in EAU
10/01/2019 - 09/30/2021 (PI)
Palatin Technologies, Inc.


Projects for the Massachusetts Lions Eye Research Fund
07/01/2014 - 05/31/2021 (PI of Sub-Project / SP)
PI: Stephen P. Christiansen, MD
Massachusetts Lions Eye Research Fund, Inc.


Manipulation of Immunity to Treat Uveitis
03/01/2016 - 02/29/2020 (PI)
NIH/National Eye Institute
5R01EY025961-04

Initial Mechanism of Action for The Therapeutic Application of Melanocortin Receptor Agonists to Suppress EAU
06/01/2018 - 12/31/2019 (PI)
Palatin Technologies, Inc.


The MC1R protein palmitoylation in melanoma development
09/19/2018 - 11/30/2019 (PI)
NIH/National Cancer Institute
5R01CA224432-02

Initial Mechanism Of Action For The Therapeutic Application Of A Melanocortin Receptor Agonists To Attenuate Retinal Damage in Diabetic Retinopathy
06/01/2017 - 12/31/2018 (PI)
Palatin Technologies, Inc.


Initial Mechanism Of Action For The Therapeutic Application Of A Melanocortin Receptor Agonists To Supress EAU
02/10/2014 - 06/30/2016 (PI)
Palatin Technologies, Inc.




Title


Yr Title Project-Sub Proj Pubs
2021 Manipulation of Immuity to Treat Uveitis 5R01EY025961-06 6
2020 Manipulation of Immuity to Treat Uveitis 2R01EY025961-05 6
2020 Manipulation of Immuity to Treat Uveitis 2R01EY025961-05 6
2019 The MC1R protein palmitoylation in melanoma development 5R01CA224432-02
2019 Manipulation of Immunity to Treat Uveitis 5R01EY025961-04 6
2018 Manipulation of Immunity to Treat Uveitis 5R01EY025961-03 6
2017 Manipulation of Immunity to Treat Uveitis 5R01EY025961-02 6
2016 Manipulation of Immunity to Treat Uveitis 1R01EY025961-01A1 6
2011 Neuroimmunomodulation within the eye 5R01EY010752-15 43
2010 Neuroimmunomodulation within the eye 7R01EY010752-14 43
Showing 10 of 30 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Taylor AW. Tailoring immune cell behavior to stop autoimmune disease. EBioMedicine. 2021 Aug; 70:103516. PMID: 34364167; PMCID: PMC8350449; DOI: 10.1016/j.ebiom.2021.103516;
     
  2. Sanjiv N, Osathanugrah P, Fraser E, Ng TF, Taylor AW. Extracellular Soluble Membranes from Retinal Pigment Epithelial Cells Mediate Apoptosis in Macrophages. Cells. 2021 May 13; 10(5).View Related Profiles. PMID: 34068205; PMCID: PMC8153131; DOI: 10.3390/cells10051193;
     
  3. Ng TF, Manhapra A, Cluckey D, Choe Y, Vajram S, Taylor AW. Melanocortin 5 Receptor Expression and Recovery of Ocular Immune Privilege after Uveitis. Ocul Immunol Inflamm. 2021 Feb 22; 1-11.View Related Profiles. PMID: 33617397
     
  4. Lužnik Z, Sun Z, Nakagawa H, Taylor AW, Jurkunas UV, Yin J, Dana R. Association of a-Melanocyte-Stimulating Hormone With Corneal Endothelial Cell Survival During Oxidative Stress and Inflammation-Induced Cell Loss in Donor Tissue. JAMA Ophthalmol. 2020 11 01; 138(11):1192-1195. PMID: 32940642; PMCID: PMC7499243; DOI: 10.1001/jamaophthalmol.2020.3413;
     
  5. Spana C, Taylor AW, Yee DG, Makhlina M, Yang W, Dodd J. Probing the Role of Melanocortin Type 1 Receptor Agonists in Diverse Immunological Diseases. Front Pharmacol. 2018; 9:1535. PMID: 30692924; PMCID: PMC6339910; DOI: 10.3389/fphar.2018.01535;
     
  6. Benque IJ, Xia P, Shannon R, Ng TF, Taylor AW. The Neuropeptides of Ocular Immune Privilege, a-MSH and NPY, Suppress Phagosome Maturation in Macrophages. Immunohorizons. 2018 Nov; 2(10):314-323.View Related Profiles. PMID: 30613828; PMCID: PMC6319950; DOI: 10.4049/immunohorizons.1800049;
     
  7. Taylor AW, Ng TF. Negative regulators that mediate ocular immune privilege. J Leukoc Biol. 2018 Feb 12.View Related Profiles. PMID: 29431864; PMCID: PMC6240388; DOI: 10.1002/JLB.3MIR0817-337R;
     
  8. Wang E, Choe Y, Ng TF, Taylor AW. Retinal Pigment Epithelial Cells Suppress Phagolysosome Activation in Macrophages. Invest Ophthalmol Vis Sci. 2017 Feb 01; 58(2):1266-1273.View Related Profiles. PMID: 28241314; PMCID: PMC5341620; DOI: 10.1167/iovs.16-21082;
     
  9. Taylor AW. Reference Module in Neuroscience and Biobehavioral Psychology. Immunosuppressive and Anti-inflammatory Molecules That Maintain Immune Privilege of the Eye. 2017. View Publication
  10. Lee DJ, Preble J, Lee S, Foster CS, Taylor AW. MC5r and A2Ar Deficiencies During Experimental Autoimmune Uveitis Identifies Distinct T cell Polarization Programs and a Biphasic Regulatory Response. Sci Rep. 2016 11 25; 6:37790. PMID: 27886238; PMCID: PMC5122918; DOI: 10.1038/srep37790;
     
Showing 10 of 98 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 98 publications over 32 distinct years, with a maximum of 8 publications in 2000

YearPublications
19871
19901
19911
19922
19942
19951
19964
19975
19982
19995
20008
20012
20027
20032
20041
20054
20065
20076
20084
20094
20106
20113
20121
20133
20143
20153
20163
20172
20182
20191
20201
20213

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

72 E. Concord St Instructional (L)
Boston MA 02118
Google Map


Taylor's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_